预约演示

Takeda to acquire Nimbus’ TYK2 inhibitor TYK2 inhibitor in deal worth $6bn

2022-12-14

临床结果上市批准疫苗临床2期并购

Takeda has announced it will acquire Nimbus Therapeutics' NDI-034858, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases, in a deal worth $6bn.

Takedathe terms of the agreement, TakNimbus TherapeuticsfrNDI-034858t of $4bn to Nimbus, which will also be eligible foTYK2o $1bn milestone payments upon achieving annual net sales autoimmune diseases

Nimbus recently announced positiveTakedaine results from a phase 2b study evaluatNimbusI-034858, which will be known as TAK-279 upon completion of the transaction, for patients with moderate-to-severe plaque psoriasis.

Nimbusrom the 259 patients dosed in the study showed that NDI-034858 achieved the priNDI-034858acy endpoint, with a statTAK-279ly significant greater proportion of patients achieving a 75% improvement plaque psoriasis– compared to placebo at 12 weeks.

Additional endpoints in the study were also achieved, NimbNDI-034858d, and the safety of NDI-034858 was consistent with other leading allosteric TYK2 inhibitors.

Takeda said it intends to present results from the study early in 2023, with NDI-034858 aNDI-034858 to enter a phase 3 study in psoriasis next yeTYK2 inhibitors TYK2

The candidate is also part of an ongoing phase 2b study in active psoriatic aNDI-034858and Takeda has outlined its plans to invepsoriasist for the treatment of inflammatory bowel disease and other autoimmune diseases.

Commenting on the acquisition, Andy Plump, president of resactive psoriatic arthritisakeda, said: “After having seen the NDI-034858 phase 2b data, particularly inflammatory bowel diseasecited by thautoimmune diseasesf this molecule within the TYK2 class, and we believe in its broad potential for people with autoimmune diseases.

“By virtue of its unique allosteric mechanism of action, NDI-034858 is both a potentTakedaighly selective TYK2 inhibitor NDI-034858tional clinical activity, a strong tolerability profile and wide therapeutic margins. NDI-034858 is a potentiallTYK2st-in-class TYK2 inhibitor across a wide range of immune mediaautoimmune diseases

Earlier this month, Takeda’s dengue vaccine candidate, QdNDI-034858003), was approved by the European CommTYK2 inhibitor TYK2on for the prevention of dengue disease in individuals aged four years and over.NDI-034858 TYK2 inhibitor TYK2

The decision, which followed denguetive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human dengue disease, made Qdenga the only dengue vaccine approved in the EU for use in individuals regardless of previous dengue exposure.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构